Table Two. Demographic Variables Among 110 Enrolled Patients.

Patients treated with placebo are compared against patients treated with any dose of 3K3A-APC. Likely due to small sample sizes, there were no differences in the distribution of any variable among the 5 dose tiers of 3K3A-APC so these were combined. Continuous variables are shown with standard deviation. * Median (IQR) NIHSS are shown due skewed nature of the observed distributions for these variables. Significance testing was not done due to the small sample sizes and exploratory intent of the trial.

	Placebo (n = 44)	3K3A-APC (n = 66)
Males	24 (55%)	29 (44%)
Caucasian	36 (82%)	52 (79%)
Hispanic/Latino	7 (16%)	4 (6%)
Age	64 (12.0)	64 (15.2)
Weight (kg)	84 (18.0)	84 (19.1)
Platelet Count ≥ 100K	42 (96%)	65 (99%)
History - Diabetes	18 (41%)	18 (27%)
History - Hypertension	33 (75%)	52 (79%)
NIHSS Prior to Recanalization	13.5 (5 – 30)	13 (5 – 30)
NIHSS Eligibility	11.5 (5 – 28)	12 (5 – 40)
Modified Rankin  - 0   - 1   - ≥ 2	41 (93%) 3 (7%) 0 (0%)	58 (88%) 8 (12%) 0 (0%)
Recanalization Therapy - IV t-PA Only   - IAT Only   - IV t-PA and IAT	24 (55%) 2 (5%) 18 (41%)	35 (53%) 3 (5%) 28 (42%)
Stroke Onset to First Therapy   - Time to t-PA Initiation   - Time to First Skin Puncture   - Time to t-PA Initiation or First   Skin Puncture	2:07 (1:01) 1:59 (0:44) 5:39 (0:21) 1:53 (0:35)	2:13 (0:58) 2:16 (0:49) 3:31 (1:37) 2:02 (1:00)